Results 221 to 230 of about 141,844 (309)

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

open access: yesRespirology, EarlyView.
ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley   +1 more source

Renal Ketogenesis Protects Against Ischemic Kidney Injury. [PDF]

open access: yesJ Am Soc Nephrol
Feola K   +7 more
europepmc   +1 more source

Toxicity of Four Common Environmental Chemicals Across Caenorhabditis elegans Life Stages Supporting the One Health Concept

open access: yesEnvironmental Toxicology, EarlyView.
ABSTRACT Pesticides and pharmaceuticals are among the most common chemical groups in waterbodies and soils, and their universal distribution raises concerns about potential adverse effects on nontarget organisms and humans. Reproductive output disruption is of particular concern, as it transposes effects from the individual to the next generations at ...
Fábio Campos   +3 more
wiley   +1 more source

Correction to: The role of purinergic P2X3 receptors and endometriosis-associated hyperalgesia. [PDF]

open access: yesPurinergic Signal
Pretto KP   +7 more
europepmc   +1 more source

Phthalate Metabolite, Mono(2‐Ethyl‐5‐Hydroxyhexyl) Phthalate (MEHHP), Promotes Uterine‐Fibroid–Associated Phenotypes in Myometrial Stem Cell‐Derived 3D Organoids

open access: yesEnvironmental Toxicology, EarlyView.
ABSTRACT This study investigates how phthalate exposure contributes to uterine fibroid (UF) development by studying the effects of the Mono‐(2‐ethyl‐5‐hydroxyhexyl) phthalate (MEHHP), a metabolite of Di(2‐ethylhexyl) phthalate, on myometrial stem cells (MMSCs).
Somayeh Vafaei   +6 more
wiley   +1 more source

Intravenous paracetamol does not have significant opioid‐sparing effects when used as part of a multimodal analgesic protocol in dogs undergoing elective orthopaedic surgery

open access: yesVeterinary Record, EarlyView.
Abstract Background Data evaluating paracetamol combined with NSAIDs in dogs are scarce. Results of clinical studies in dogs investigating intravenous paracetamol vary. Methods Dogs were randomised to either receive 10 mg/kg paracetamol intravenously after induction of anaesthesia and every 8 hours during hospitalisation (test) or not (control).
Robin Stallard   +2 more
wiley   +1 more source

Evaluation of Systemic Nonsteroidal Anti-inflammatory Drugs on Orthodontic Tooth Movement Rate: A Clinical and Biomarker-Based Study.

open access: yesJ Pharm Bioallied Sci
Alam MK   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy